Abbott Launches First FDA-Approved Dual-Monitoring Continuous Glucose Monitor
On September 2, 2026, Abbott announced the launch of its Libre Duo continuous glucose monitor (CGM), which is now the first device authorized by the U.S. Food and Drug Administration to simultaneously track both blood glucose levels and ketone concentrations in diabetics. The new sensor aims to help prevent diabetic ketoacidosis (DKA) — a serious condition where excessive ketones make the blood too acidic, often leading to hospitalization. Abbott's Libre Duo is designed for 10-day use and requires a prescription. It functions similarly to Abbott’s existing CGMs but adds an important layer of monitoring by detecting beta-hydroxybutyrate — one of the primary ketone bodies in the blood. This feature could help diabetics identify early signs of DKA, which can be difficult to detect due to symptoms resembling those of a flu or infection. The device is intended as a proactive health tool for both Type 1 and Type 2 diabetes patients by providing real-time alerts when glucose levels are out of range. Abbott's Vice President Mark Taub emphasized the growing prevalence of DKA-related hospitalizations, highlighting the potential impact of this new technology in improving patient outcomes.
Tickers: $ABT
Topics: Continuous Glucose Monitors Diabetes Management FDA Authorization